Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients

Ziga-Smajic, Nermina; Škrbo, Selma; Muratović, Salko; Pehlivanovic, Belma; Lagumdžija, Dina; Omerović, Naida

doi:10.5455/medarh.2020.74.172-176

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the risks for other renal outcomes were similar. In asymptomatic hyperuricemic patients without gout, febuxostat was found to reduce the risk of macroalbuminuria development or worsening [22].…”

Section: Renal Injury and Signaling Pathwaysmentioning

confidence: 96%

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application

Kraev,

Geneva-Popova,

Hristov

et al. 2023

Life

View full text Add to dashboard Cite

Febuxostat, initially developed as a xanthine oxidase inhibitor to address hyperuricemia in gout patients, has evolved into a versatile therapeutic agent with multifaceted applications. This review provides a comprehensive overview of febuxostat’s mechanism of action, its effectiveness in gout management, its cardiovascular safety profile, renal and hepatic effects, musculoskeletal applications, safety considerations, and emerging research prospects. Febuxostat’s primary mechanism involves selective inhibition of xanthine oxidase, resulting in reduced uric acid production. Its pharmacokinetics require personalized dosing strategies based on individual characteristics. In gout management, febuxostat offers a compelling alternative, effectively lowering uric acid levels, relieving symptoms, and supporting long-term control, especially for patients intolerant to allopurinol. Recent studies have demonstrated its cardiovascular safety, and it exhibits minimal hepatotoxicity, making it suitable for those with liver comorbidities. Febuxostat’s potential nephroprotective effects and kidney stone prevention properties are noteworthy, particularly for gout patients with renal concerns. Beyond gout, its anti-inflammatory properties hint at applications in musculoskeletal conditions and a broader spectrum of clinical contexts, including metabolic syndrome. Emerging research explores febuxostat’s roles in cardiovascular health, neurological disorders, rheumatoid arthritis, and cancer therapy, driven by its anti-inflammatory and antioxidative properties. Future directions include personalized medicine, combination therapies, mechanistic insights, and ongoing long-term safety monitoring, collectively illuminating the promising landscape of febuxostat’s multifaceted therapeutic potential.

show abstract

Section: Renal Injury and Signaling Pathwaysmentioning

confidence: 96%

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application

Kraev,

Geneva-Popova,

Hristov

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…However, allopurinol use causes a substantial increase in triglyceride values after three and six months. Contrarily, febuxostat intake causes a noticeable decrease in TG levels for the initial three months but this decrease was not significant after six months [ 45 ]. Another study reported that febuxostat decreased serum cholesterol values effectively compared to allopurinol but both drugs’ performance was comparable in ameliorating LDL and HDL cholesterol [ 46 ].…”

Section: Reviewmentioning

confidence: 99%

The Cellular Genesis of Metabolic Syndrome and the Role of Anti-urate Drugs in Hyperuricemia Patients: A Systematic Review

Malik,

Ganatra,

Siby

et al. 2024

Cureus

View full text Add to dashboard Cite

Hyperuricemia results due to the underexcretion of uric acid through kidneys or overproduction due to either intake of purine-rich foods, a high caloric diet, or a decreased activity of purine recycler hypoxanthine-guanine phosphoribosyl transferase (HGPRT). Increased xanthine oxidoreductase (XOR) enzyme activity may contribute to hyperuricemia. Literature provides growing evidence that an independent component that contributes to the development of metabolic syndrome (MetS) and associated comorbidities is hyperuricemia. Thus, precise cellular mechanisms involved during MetS and related comorbidities in hyperuricemia, and the role of anti-urate medicines in these mechanisms require further investigations. We searched online libraries PubMed and Google Scholar for data collection. We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines for literature identification, selection, screening, and determining eligibility to produce unbiased meaningful outcomes. We applied quality assessment tools for the quality appraisal of the studies. And, outcomes were extracted from the selected studies, which revealed the relationship between hyperuricemia and MetS components by causing inflammation, endothelial dysfunction, oxidative stress, and endoplasmic reticulum stress. The selected studies reflected the role of xanthine oxide (XO) inhibitors beyond inhibition. This systematic review concluded that hyperuricemia independently causes inflammation, oxidative stress, endothelial damage, and endoplasmic reticulum stress in patients with hyperuricemia. These mechanisms provide a cellular basis for metabolic syndrome and related comorbidities. In this context, XO inhibitors and their beneficial effects go beyond XOR inhibition to ameliorate these pathological mechanisms.

show abstract